Nitorum Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Nitorum Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-69,626	Closed	-$19M	–	29
2024 Q2	$19M	Sell	69,626 -42,027	-38%	-$12.2M	2.07%	24
2024 Q1	$38.6M	Sell	111,653 -23,251	-17%	-$7.65M	3.93%	10
2023 Q4	$43.6M	Sell	134,904 -17,529	-11%	-$5.49M	4.66%	8
2023 Q3	$54.6M	Sell	152,433 -29,420	-16%	-$11.4M	5.97%	3
2023 Q2	$68.9M	Buy	181,853 +27,617	+18%	+$11.2M	6.97%	3
2023 Q1	$73.9M	Sell	154,236 -66,021	-30%	-$30.9M	7.83%	2
2022 Q4	$92.6M	Buy	220,257 +14,800	+7%	+$5.97M	8.73%	1
2022 Q3	$85.7M	Buy	205,457 +17,000	+9%	+$8.48M	7.46%	2
2022 Q2	$93.3M	Buy	188,457 +77,900	+70%	+$40.6M	6.87%	3
2022 Q1	$62.3M	Buy	+110,557	New	+$66.6M	4.13%	9

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nitorum Capital's BIO Position: Q3 2024 in Review

Nitorum Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 69,626 shares — an estimated $19M sold.

Nitorum Capital first reported a position in BIO in Q1 2022 and held it in 10 quarters. The position peaked at $93.3M in Q2 2022. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

Nitorum Capital reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
Nitorum Capital sold 69,626 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $19M.
Nitorum Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2022 and held it in 10 quarters.
Nitorum Capital's Bio-Rad Laboratories Class A position peaked at $93.3M in Q2 2022.
438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Nitorum Capital's 13F filing for Q3 2024, filed 14 Nov 2024.